Philip Goulder
Overview
Explore the profile of Philip Goulder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
5921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson C, Crichton S, Judd A, Bamford A, Goulder P, Klein N, et al.
AIDS
. 2025 Feb;
PMID: 39912745
Objectives: To estimate the probability of long-term nonprogression (LTNP) in the absence of antiretroviral treatment (ART) in children with perinatally acquired HIV, and the impact of LTNP definitions on these...
2.
Bengu N, Cromhout G, Adland E, Govender K, Herbert N, Lim N, et al.
Nat Med
. 2025 Feb;
PMID: 39910274
No abstract available.
3.
Kuhn L, Barnabas S, Cotugno N, Peay H, Goulder P, Cotton M, et al.
Lancet HIV
. 2024 Jul;
11(10):e700-e710.
PMID: 39059402
Analytical treatment interruption (ATI) is widely acknowledged as an essential component of studies to advance our understanding of HIV cure, but discussion has largely been focused on adults. To address...
4.
Bengu N, Cromhout G, Adland E, Govender K, Herbert N, Lim N, et al.
Nat Med
. 2024 Jun;
30(10):2796-2804.
PMID: 38843818
After sporadic reports of post-treatment control of HIV in children who initiated combination anti-retroviral therapy (cART) early, we prospectively studied 284 very-early-cART-treated children from KwaZulu-Natal, South Africa, after vertical HIV...
5.
Liu C, Zhou D, Dijokaite-Guraliuc A, Supasa P, Duyvesteyn H, Ginn H, et al.
Cell Rep Med
. 2024 May;
5(5):101553.
PMID: 38723626
BA.2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains many mutations in the spike gene. It appears to have originated from BA.2 and is distinct from the XBB variants responsible...
6.
Zacharopoulou P, Lee M, Oliveira T, Thornhill J, Robinson N, Brown H, et al.
Front Immunol
. 2024 Apr;
15:1352123.
PMID: 38562938
Broadly neutralising antibodies (bNAbs) targeting HIV show promise for both prevention of infection and treatment. Among these, 10-1074 has shown potential in neutralising a wide range of HIV strains. However,...
7.
Sampson O, Jay C, Adland E, Csala A, Lim N, Ebbrecht S, et al.
Front Immunol
. 2024 Mar;
15:1329805.
PMID: 38481993
mRNA vaccine technologies introduced following the SARS-CoV-2 pandemic have highlighted the need to better understand the interaction of adjuvants and the early innate immune response. Type I interferon (IFN-I) is...
8.
Jay C, Adland E, Csala A, Lim N, Longet S, Ogbe A, et al.
Front Immunol
. 2023 Nov;
14:1248630.
PMID: 37942333
Introduction: The key to understanding the COVID-19 correlates of protection is assessing vaccine-induced immunity in different demographic groups. Young people are at a lower risk of COVID-19 mortality, females are...
9.
Jay C, Adland E, Csala A, Dold C, Edmans M, Hackstein C, et al.
Front Immunol
. 2023 Sep;
14:1248658.
PMID: 37711627
Introduction: Family studies of antiviral immunity provide an opportunity to assess virus-specific immunity in infected and highly exposed individuals, as well as to examine the dynamics of viral infection within...
10.
Johnson S, Phillips E, Adele S, Longet S, Malone T, Mason C, et al.
Clin Exp Immunol
. 2023 Feb;
212(3):249-261.
PMID: 36807499
T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T-cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to...